Articles tagged with: Sapacitabine
Featured, Headline, News »
This year’s American Society of Hematology meeting took place last week in Orlando. December 4 was the first full day of the conference, and it included several talks as well as a poster session related to myelodysplastic syndromes.
Education Program
The first myelodysplastic syndromes (MDS)-related event was an education program in the afternoon. The same session was also held Sunday morning.
First, Dr. Guillermo Garcia-Manero from the M.D. Anderson Cancer Center in Houston spoke about prognostic scoring systems for MDS. He said that it is important for physicians to explain…
Headline, News »
Several important myelodysplastic syndromes (MDS) studies were presented at the annual American Society of Clinical Oncology (ASCO) annual meeting on June 7. The meeting was held June 4 to 8 in Chicago.
Monday, June 7
As part of Monday’s morning session about leukemia, myelodysplasia, and transplantation, two important studies were presented and then discussed.
The first study, which looked at Vidaza (azacitidine) treatment in high-risk patients, was presented by Dr. Alan List of the Lee Moffitt Cancer Center and Research Institute. The results showed that Vidaza significantly…
Featured, Headline, News »
Researchers yesterday presented interim results of an ongoing Phase 2 clinical trial of sapacitabine. The clinical trial is being conducted with myelodysplastic syndromes (MDS) patients who are resistant to treatment with Vidaza (azacitidine) or Dacogen (decitabine). Researchers presented the trial results at the American Society of Clinical Oncology (ASCO) 2010 annual meeting in Chicago.
Sapacitabine is a new drug being developed by Cyclacel Pharmaceuticals as a potential treatment for MDS and acute myeloid leukemia. Sapacitabine damages the DNA of cancer cells and prevents the cells from multiplying.
The trial…
News »
Telik Announces Phase 1 Study Of Telintra And Revlimid Combination Therapy for Myelodysplastic Syndromes Patients — Telik, Inc. announced the start of a Phase 1 clinical trial to test the safety, tolerability, and maximum tolerable dose of Telintra (ezatiostat hydrochloride) in combination with Revlimid (lenalidomide) for myelodysplastic syndromes (MDS) patients. Thirty low to intermediate-1 risk MDS patients will receive Telintra in increasing doses. The drug has recently shown positive results for MDS patients as a single agent, either orally or by intravenous injection, and continues to be evaluated as a single agent in a separate Phase 2 study. For more information, please see the Telik press release.
Company Developing Sapacitabine For Treatment Of Myelodysplastic Syndromes To Raise Millions In Direct Offerings — Cyclacel Pharmaceuticals, Inc. announced plans on January 21 to raise up to $7.9 million in capital through registered direct offerings to its investors. The company is currently testing sapacitabine for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and several other cancers. Interim results of an ongoing Phase 2 clinical trial in MDS were presented at the recent American Society of Hematology annual meeting (see related Beacon news). For more information, please see the Cyclacel press release.
Understanding Clinical Trials For Blood Cancers Like Myelodysplastic Syndromes, LLS Web Seminar — The Leukemia and Lymphoma Society (LLS) is sponsoring an online seminar (webinar) titled “Understanding Clinical Trials For Blood Cancers” on Thursday, January 28, from 7 p.m. to 8 p.m. EST. Dr. Karen Yee will explain clinical trials in detail, including how they are organized, safety concerns, and how myelodysplastic syndromes patients can participate. Registration is required. For more information, please visit the LLS Web site.
For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.
Headline, News »
Interim results from an ongoing Phase 2 study show that sapacitabine produces a response at three different dosing levels in myelodysplastic syndromes (MDS) patients. The findings were presented as a poster at the American Society of Hematology 2009 annual meeting on December 5.
Sapacitabine is an orally-administered drug that mimics naturally-occurring chemical structures in the body and helps stop abnormal cell division that is characteristic of MDS or acute myeloid leukemia (AML). It is currently being investigated for the treatment of MDS and AML.
The…